Kornimate/medical-research-clean huggingface dataset:
screening for heart failure in general medicine consultations

Conditions: Heart Failure

Summary: heart failure poses a significant public health challenge due to its high prevalence and the substantial human and financial costs it generates. furthermore, the lack of clear screening guidelines and challenges in accessing care and multi-professional coordination, contribute to diagnostic delays, leading more patients to seek care in more severe clinical states and requiring direct admission to emergency departments. there is therefore also a major organizational challenge in better managing the entry of patients into the healthcare system. this necessitates the development of structured heart failure screening strategies. the 2021 european society of cardiology (esc 2021) guidelines on heart failure screening prioritize the identification of at-risk individuals and the early detection of disease manifestations. they suggest that, in high-risk groups, tests such as echocardiography and biomarker measurement (nt-probnp) should be used to detect heart failure at an early stage, even in the absence of symptoms. the guidelines also delineate specific biomarker thresholds and propose organizational frameworks with defined timelines to facilitate systematic screening. the implementation of a heart failure screening pathway within primary care involving multi-professional cooperation is therefore warranted. stratifying screening based on risk factors and symptomatology is expected to enhance the positive predictive value of the screening process. furthermore, evaluating the efficacy of this pathway is crucial for establishing a standardized, reproducible clinical protocol suitable for routine primary care practice. this study is a prospective, multicenter, observational study conducted within the context of routine clinical care.


Eligibility criteria:
inclusion criteria: 1. patient consulting in general practice. 2. aged 65 years or older exclusion criteria: 1. known heart failure. 2. patient who has already consulted a cardiologist within the last 12 months. 3. patient opposition to participate in the study

Keywords: heart failure screening general medicine care pathway multi-professional cooperation
volatile organic compounds in staphylococcus aureus patients

Conditions: Staphylococcus Aureus; Methicillin-resistant Staphylococcus Aureus; Nosocomial Disease

Summary: the znose® mrsa test is a non-invasive breath test for markers of staphylococcus aureus, which may predict the probability of bacterial organisms in the anterior nares, throat and respiratory tract, wounds, and anus and therefore be able to replace or supplement current active methicillin resistant staphylococcus aureus (mrsa) surveillance efforts. it consists of: * a collection apparatus for collection of volatile compounds from suspected infection sites onto a sorbent trap or tedlar bag, as well as for the collection of a separate sample of room air. * analysis of the volatile organic compounds from suspected infection sites and room air by short acoustic wave gas chromatography. * interpretation of the volatile organic compounds with a proprietary algorithm in order to predict the probability of staphylococcus aureus infection and colonization. this study will test the hypothesis that we can identify the presence of mrsa by sampling the "head space" above culture media of anterior nare samples provided by patients with mrsa. additionally, this study will test the hypothesis that we can identify the presence of mrsa by sampling air exhaled through the nostrils (nasal exhalant).


Eligibility criteria:
inclusion criteria: * suspicion of staphylococcus aureus infection or colonization * able to give samples for znose® analysis exclusion criteria: * inability to provide sample for znose® analysis

Keywords: staphylococcus aureus methicillin-resistant staphylococcus aureus nosocomial disease electronic nose gas chromatography
evaluating parent delivered interventions for children with autism

Conditions: Autistic Disorder; Developmental Disabilities

Summary: the investigators will assess the efficacy of parent delivered interventions in the treatment of social and communication deficits in children with autism. by collecting information about parent and child functioning before and after intervention, the investigators will be able to determine whether the intervention is effective in improving child social communication and reducing parent stress.


Eligibility criteria:
inclusion criteria for autism participants: * children between the ages of 1.6 and 17.11 years of age * males and females * diagnosis of autism based on dsm-iv-tr criteria, an expert clinical evaluation, and ados or adi-r if needed * receiving or will receive a parent delivered intervention to alleviate symptoms related to their diagnosis of autistic disorder * have a care provider that will reliably bring subjects to their chosen intervention and clinic visits, and is trustworthy to provide accurate accounts of services provided to the subject inclusion criteria for developmentally delayed participants: * will have an age range between 1.6 and 17.11 years of age * males or females * diagnosis of a developmental delay or disorder based on dsm-iv-tr, icd-10, and an expert clinical evaluation * have historical evidence of significant abnormal developmental milestones as determined by neurological history * receiving or will receive a parent delivered intervention * have a care provider that will reliably bring subjects to their chosen intervention and clinic visits, and is trustworthy to provide accurate accounts of services provided to the subject exclusion criteria for autism participants: * is medically unstable (e.g., more than one seizure a month) * have a medical diagnosis that causes autism like symptomology (e.g., fragile x, down syndrome, angelman's syndrome, tuberous sclerosis, rett's disorder) exclusion criteria for developmentally delayed subjects: * is medically unstable (e.g., more than one seizure a month) * has a diagnosis of asd
the effect of myofascial release technique on sportive performance, balance and injury risk in runners

Conditions: Runt

Summary: in order to investigate the effect of myofascial release technique on sportive performance, balance and injury risk in runners, 49 athletes will include in the study. the myofascial application group (n=26)will receive 12 sessions of 6-weekly lower extremity posterior muscle therapy. the control group (n=23) will continue the routine exercise program.

running is a sport that involves repetitive movement and is particularly vulnerable to injury in the lower extremities. myofascial release, on the other hand, is a manual method that is effective in increasing blood and oxygen permeability between tissues, renewing the tissue, protecting it from injury and increasing performance. the aim of our study is to investigate the effect of myofascial application on sportive performance balance and injury risk in runners. the study will carry out on runners with a 3-month running history. myofascial application group (n=26) and control group (n=23) will divide into two groups as randomized controlled. my jump 2 app, y balance test and functional movement analysis (fms) will use as assessment methods. the myofascial application group will receive 12 sessions of 6 weeks of therapy for the lower extremity posterior group muscles. the control group will continue the routine exercise program.

Eligibility criteria:
inclusion criteria: * have a running history of more than 3 months * be between 18 and 45 years old * being a healthy individual without chronic disease * no acute injury affecting the lower extremity * running at least 5 km a week * willingness to participate in the research exclusion criteria: * pregnancy or suspected pregnancy * use of alcohol or active substance * having another ongoing treatment process * having a history of surgery on the lower extremity * refusal to participate in the study

Keywords: myofascial release run performance balance injury risk fascia
mortality in pediatric intensive care unit

Conditions: Intensive Care Units, Pediatric

Summary: with the development of national economy and medical technology, patients can extend life rely on high-end medical facilities. at the same time, the continued treatment cannot bring benefits to children, even resulting in poor quality of life of children and bringing high medical costs. this makes the limited medical resources are unreasonable distributed. research showed that picu mortality rate halved over ten years ago, but the data did not include death cases who left hospital before death. however, the death number of out-hospital were more than death in-hospital. therefore, the data cannot actually reflect china's mortality rate of picu. the reason analysis was limited to the cause of the disease, and does not take the social, economic factors into account. this study include eight picus of children's hospital picu. critically ill patients are prospectively studied from death risk factors, admission status, disease diagnosis, severity of illness, analyzing of the risk factors of death from disease diagnosis and death risk factors. in addition, we will illuminate the relationship of death and economic factor, especially for who died out-hospital after withdraw or stop treatment.


Eligibility criteria:
inclusion criteria: * all patients admitted to the picu of eight study centers exclusion criteria: * postoperative monitoring of patients with stable hemodynamics * pcis score \>90 and not up to the united states picu admission standards
va111913 dysmenorrhoea efficacy and safety proof of concept

Conditions: Primary Dysmenorrhea

Summary: the purpose of the study is to investigate how effective va111913 is at preventing menstrual pain in women with primary dysmenorrhoea.

dysmenorrhoea is suffered by between 50% and 90% of women of child bearing age. up to 30% of these women are non-responsive to the currently prescribed therapies. as such it represents an area of unmet medical need. va111913 inhibits vasopressin-induced contractions of human myometrial strips and human myometrial blood vessels in vitro. by this mechanism, it is anticipated that the pain of dysmenorrhoea, a condition in which myometrial tone and contractions are increased and blood flow to the uterus is decreased compared to normal, may be reduced. subjects will be dosed with va111913 ts and placebo in a cross over design during two consecutive menstrual cycles. they will be dosed for up to a maximum of 6 days, beginning 2 days before the onset of menstruation. subjects will then assess the menstrual pain, bleeding and amount of analgesia required to treat symptoms during each cycle

Eligibility criteria:
inclusion criteria: * women between 18 and 35 years old * not pregnant * history of primary dysmenorrhoea * regular menstrual cycles * signed informed consent exclusion criteria: * known secondary dysmenorrhoea * concomitant use of regular prescription or non prescription medications or herbal remedies * any clinically significant medical history or active disease * participation in another clinical study in the last 3 months * contraindication to chosen rescue medications or allergy to their constituents * other protocol defined eligibility criteria may apply

Keywords: dysmenorrhoea dysmenorrhea pain pre-emptive
qst for corneal nerve function

Conditions: Corneal Disease; Neuropathy; Dry Eye Disease; Neurotrophic Keratitis

Summary: this study is designed to learn more about the impact different types of stimuli, such as heat, cold and vibration, can have on ocular pain response. this is called quantitative sensory testing (qst). most procedures being performed in this study, except the qst, are standard of care which means they are performed during the participant's routine eye examination.

quantitative sensory test (qst) is a non-invasive neurophysiological method that refers to a group of procedures that assess the perceptual responses to systematically applied and quantifiable sensory stimuli for the purpose of characterizing somatosensory function or dysfunction. in this study, we propose to evaluate corneal nerve functions in patients with corneal nerve abnormalities by qst and correlate the nerve functions with symptoms, clinical signs and nerve morphology detected by in-vivo confocal microscopy (ivcm). identification of corneal nerve functions and correlations with other findings may help us to understand underlying pathological mechanisms of the disease and may guide us toward new treatment targets. we hypothesize that, qst may provide us detailed information about corneal nerve function alterations and may correlate with morphological nerve changes detected by ivcm.

Eligibility criteria:
inclusion criteria: group 1: stage i neurotrophic keratopathy (nk) 1. clinical findings of stage i nk 2. decreased nerve density by ivcm 3. decreased corneal sensation group 2: stage ii nk 1. clinical findings of stage ii nk 2. decreased nerve density by ivcm 3. decreased corneal sensation group 3: dry eye disease (ded) 1. symptoms of ded at least 3 months 2. presence of at least one of the following ded signs; tear film break-up time lower than 7, ocular surface staining more than +1 based on nih scale 3. normal or mildly effected corneal sensation group 4: healthy individuals 1. absence of any ocular surface symptoms 2. absence of ocular surface findings 3. transparent and clear cornea 4. normal corneal sensation group 5: ncp 1. presence of neuropathic symptoms and 2. symptoms out of proportion to clinical findings and 3. nerve abnormalities detected by in vivo confocal microscopy exclusion criteria: 1. history of diabetes 2. history of ocular surgery, corneal infection, or corneal injury within the last 3 months 3. systemic regular anti-inflammatory and/or steroid and/or immune-modulatory therapy in the last 3 months 4. active ocular allergies 5. any major psychiatric illness including bipolar, psychosis, obsessive-compulsive disorder and major depression 6. pregnancy 7. history of surgery within the last 3 months 8. history of , sarcoidosis, gvhd or collagen vascular disease 9. allergic to benzalkonium chloride "bak" (an eye-drop preservative) 10. concurrent enrollment in other studies that in the opinion of the investigator will interfere with the results of this study 11. non-english speakers

Keywords: quantitative sensory test
qstat in liver transplant

Conditions: Blood Loss, Surgical

Summary: this study will assess the clinical performance of the quantra system with the qstat cartridge in the liver transplant population.

the quantra system is a fully integrated and automated in vitro diagnostic device which uses seer sonorheometry, an ultrasound-based technology, to characterize the viscoelastic propoerties of a whole blood sample during coagulation. the quantra qstat cartridge was developed to monitor hemostasis in the trauma and liver transplant populations which may experience a range of coagulopathies of various etiologies including fibrinolytic defects. this single-center, prospective, observational stuey will evaluate the performance of the quantra system with the qstat cartridge as compared to corresponding measures determined using the teg 5000.

Eligibility criteria:
inclusion criteria: * subject is ≥ 18 years of age * subject is undergoing deceased donor liver transplant and is a candidate for a teg test to be performed to access coagulopathy during surgery. * subject is willing to participate, and is willing to consent (either prospectively or by deferred consent) exclusion criteria: * subject is younger than 18 years of age * subject is known to have received antifibrinolytic therapy immediately prior to the start of liver transplantation surgery. * subject is unable to provide written informed consent (either prior to performing any study related procedures or by deferred consent) * subject is currently enrolled in a distinct study that might confound the results of the proposed study * subject is affected by a condition that, in the opinion of the clinical team, may pose additional risks

Keywords: viscoelastic testing coagulation quantra hemostasis
frailty and postoperative outcomes after emergency general surgery

Conditions: General Surgery; Geriatrics; Outcomes Research

Summary: the investigators will examine the association between preoperative frailty and postoperative outcomes and resource utilization after emergency general surgery.


Eligibility criteria:
inclusion criteria: * all residents of ontario aged more than 65 years on their surgery date with valid provincial health insurance who have an emergency general surgery procedure (large bowel surgery, small bowel surgery, cholecystectomy, control of hemorrhage from duodenal ulcer, lysis of adhesions, appendectomy, laparotomy) exclusion criteria: * no valid provincial health insurance
biodulse ii: the effect of an irish seaweed protein extract on glucose control in adults with type 2 diabetes

Conditions: Type 2 Diabetes

Summary: co-ingesting protein with carbohydrate is an effective way to improve postprandial glucose handling. the investigators have isolated and identified a bioactive protein extracted from seaweed. the investigators aim to explore how varying doses of seaweed protein influence postprandial glycaemia and insulinaemia in a population with type 2 diabetes.


Eligibility criteria:
inclusion criteria: * aged 18-67 exclusion criteria: * terminal disease * exclusively receiving enteral or parenteral nutrition * any conditions/anomalies that are contraindications to bioelectrical impedance analysis as per institutional risk assessment and standard operating procedures * past medical history of cancer, neurological, kidney, pulmonary, digestive (coeliac disease), thyroidal disease, cognitive impairment
effect of vitamin supplementation in glaucoma patients

Conditions: Glaucoma; Homocysteinemia; Elevated Retinal Venous Pressure; Abnormal Steady State Pattern Electroretinography

Summary: the impact of targeted vitamin supplementation on retinal venous pressure (rvp) and steady state pattern erg (ssperg) in patients with rvp 15mmhg or more above intra-ocular pressure (iop) and serum homocystein 12µmol/l or more, with signs of progression in spite of adequate iop control, as evidenced by ssperg abnormality with or without structural progression or visual field progression,

provided the inclusion criteria were met, rvp measurement was repeated, and a 1 capsule/day regimen of ocufolin® forte was subsequently carried out for a duration of 3 months, after which repeat measurements of iop, ssperg, and rvp were performed, along with dilated fundoscopy. .

Eligibility criteria:
inclusion criteria: * glaucoma and/or ocular vascular disease in at least on eye * abnormal ssperg * rvp measured using an ophthalmodynamometer at least 15 mmhg higher than intra-ocular pressure (iop), * fasting serum hcy level \> 12 µmol/l * stable and well-controlled iop (with or without iop-lowering treatment) exclusion criteria: * starting other systemic or ocular medications with potential impacts on rvp within a month before entering the study or during the course of the study * starting or changing the dosage of other medications with potential impact on ssperg within 3 months before entering the study or during the course of the study * non-adherence to the follow-up schedule * inability to perform a proper rvp measurement using ophthalmodynamometry.

Keywords: glaucoma homocysteine plasma levels l-methylfolate ophthalmodynamometry retinal venous pressure (rvp) steady state pattern electroretinography
the effect of covid-19 pandemia on follow up of patients with chronic kidney disease

Conditions: Covid19; Chronic Kidney Diseases; Proteinuria

Summary: covid-19 pandemic affected the admission of patients to the hospital especially the older patients (\> 65 years old) because of curfews and the reluctance of patients to apply to the hospitals. chronic kidney disease is characterized with the progressive loss of kidney function over the time and regular follow-up of patients for their kidney function and treatment of complications is recommended in these patients.

the chronis kidney disease patients followed in nephrology outpatient unit are going to be enrolled in the study and their kidney functions (calculated with the mdrd formula to asses the estimated glomerular filtration rate (egfr)) will be evaluated 6 months before and after the covid-19 pandemia. and the rate of initiation of renal replacement therapies and the change in proteinuria will be evaluated 6 months before and after the covid-19 pandemic.

Eligibility criteria:
inclusion criteria: * patients with chronic kidney disease on regular follow-up for 6 months before the covid19 pandemic. exclusion criteria: * patients without chronic kidney disease * patients not on routine follow-up for 6 months before the covid19 pandemic
programmed intermittent epidural bolus versus continuous infusion in labour analgesia

Conditions: Labor Pain

Summary: this study aims to establish if programmed intermittent epidural bolus combined to patient controlled analgesia in labour analgesia will lower the hourly bupivacaine consumption when compared to continuous infusion combined with patient controlled analgesia. the investigators' hypothesis is that the use of programmed intermittent epidural bolus will lower the hourly bupivacaine consumption.

patients are randomised to receive either a programmed bolus of 6ml each 45 minutes or a continuous infusion of 8ml/h. in each group, they have the possibility to add a pcea bolus of 6ml every 20min as needed.

Eligibility criteria:
inclusion criteria: * pregnant nulliparous or multiparous woman in labour * age ≥18 years * obtained consent for epidural analgesia * asa classification i-ii-iii * early labour (cervical dilation ≤6cm) exclusion criteria: * pregnancy-related comorbidities (preeclampsia, eclampsia, gestational diabetes, large for gestational age fetus) * prematurity (\<36 weeks of gestation) * multiple gestation * fentanyl allergy or hypersensitivity * patient unable to understand the pcea * fetal breech position * maternal cardiac pathology and contraindication to valsalva manoeuvre * patient with a pain visual analog scale (vas) not ≤1/10 20 minutes after the anesthesiologist's initial bolus * intrathecal catheter or intravascular catheter * accidental dural puncture * patient refusal * patient with a history of chronic pain (pain lasting more than 3 months) or fibromyalgia
the microbiome in subfertility and assisted reproductive technologies (art)

Conditions: Infertility; Subfertility

Summary: to assess the impact of the female genital microbiome on art outcome.

the main objective of this study is to learn more about which microbial spectra are negatively or positively impacting ivf pregnancy outcome. this information is needed before proceeding to the next step in which an adaptation of the microbiome can be attempted to improve ivf outcome. the study is expected to shed light over the possible influence of the microbiome on causes for subfertility, endometrial receptivity and obstetrical complications. a diagnostic link may be found with entities that are often unexplained today, e.g. (recurrent) miscarriage and repeated implantation failure.

Eligibility criteria:
inclusion criteria: 1. caucasian women 2. women undergoing an in-vitro fertilization cycle (for the first or second time) 3. single embryo transfer 4. day 5 embryo transfer 5. gonadotropin-releasing hormone antagonist 6. anti-mullerian hormone \> 0,69 and \< 3,5 µg/l 7. body mass index ≤ 30 kg/m2 8. signed informed consent exclusion criteria: 1. women suffering of chronic diseases which may impair pregnancy outcome (e.g. diabetes, chronic renal disease). 2. antibiotics within 3 weeks of sampling 3. surgical sperm retrieval 4. in-vitro maturation 5. preimplantation genetic diagnosis 6. grade 3 or 4 endometriosis 7. patients unable to comprehend the investigational nature of the proposed study

Keywords: assisted reproductive technologies microbiome